The global Major Depressive Disorder (MDD) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Major Depressive Disorder (MDD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Report Sample includes:
- Table of Contents
- List of Tables & Figures
- Charts
- Research Methodology
Get FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-major-depressive-disorder-forecast-2023-2030-68
The China market for Global Major Depressive Disorder (MDD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Major Depressive Disorder (MDD) market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
This report aims to provide a comprehensive presentation of the global market for Major Depressive Disorder (MDD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Major Depressive Disorder (MDD). This report contains market size and forecasts of Major Depressive Disorder (MDD) in global, including the following market information:
Global Major Depressive Disorder (MDD) Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
We surveyed the Major Depressive Disorder (MDD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks. Total Market by Segment:
Global Major Depressive Disorder (MDD) Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Major Depressive Disorder (MDD) Market Segment Percentages, by Type, 2022 (%)
Antidepressant Drugs
SSRIs
SNRIs
Benzodiazepines
Others
Global Major Depressive Disorder (MDD) Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Major Depressive Disorder (MDD) Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Major Depressive Disorder (MDD) Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Major Depressive Disorder (MDD) Market Segment Percentages, By Region and Country, 2022 (%)
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
The Middle East and Africa (Middle East, Africa)
South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Major Depressive Disorder (MDD) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Major Depressive Disorder (MDD) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
GlaxoSmithKline
Merck
AstraZeneca
Eli Lily
Johnson & Johnson
Forest Laboratories
Sanofi-Aventis
H. Lundbeck
Bristol-Myers Squibb
Chapter 1: Introduces the definition of Major Depressive Disorder (MDD), market overview.
Chapter 2: Global Major Depressive Disorder (MDD) market size in revenue.
Chapter 3: Detailed analysis of Major Depressive Disorder (MDD) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Major Depressive Disorder (MDD) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
Get the Complete Report & TOC at https://www.24marketreports.com/life-sciences/global-major-depressive-disorder-forecast-2023-2030-68
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Follow Us On linkedin :-https://www.linkedin.com/company/24-market-reports
Comments